Longevity Clinic Finder logo
Find Clinics
Browse Locations
Browse ServicesGuidesEvents
Register Your ClinicRegister ClinicSign In
Find ClinicsBrowse LocationsBrowse ServicesGuidesEvents
For Providers
Claim Your Clinic (Free)Upgrade Your VisibilityProvider Login
Register Your ClinicSign In
  1. Home
  2. Guides
  3. Treatments
  4. Weight Management
Longevity Clinic Finder logo

A global directory connecting individuals with longevity, wellness, and preventive health clinics. Discover treatments, explore providers, and find clinics near you or around the world.

  • GLP-1 and Other Anti-Obesity Medications
  • Weight Management

    GLP-1 and Other Anti-Obesity Medications

    GLP-1 and other anti-obesity drugs need an FDA-approved product, monitoring, and a protein-and-strength plan. Compounded copies are not the same.

    Written by LCF Staff3 min readUpdated October 5, 2026

    Educational Guidance Notice

    This dossier is published for general educational reference and biomarker understanding only. It does not constitute individual medical diagnosis or care. Longevity Clinic Finder does not deliver direct clinical therapy. Consult an accredited board-certified physician before booking Weight Management.

    Review Medical Disclaimers →
    GLP-1 and Other Anti-Obesity Medications

    Overview

    Anti-obesity medication management is licensed prescribing and follow-up for FDA-approved chronic weight-management drugs—not a cash vial and a scale photo. NIDDK lists incretin options such as GLP-1 receptor agonists and dual GIP/GLP-1 therapy, plus non-incretin medicines including phentermine/topiramate extended-release, naltrexone/bupropion, and orlistat. Product labels differ. Selection depends on cardiovascular disease, diabetes, blood pressure, seizure or eating-disorder history, pregnancy plans, gallbladder or pancreatitis history, interactions, and cost. NIDDK is explicit: do not take these medicines only to change appearance. Semaglutide and tirzepatide products used for diabetes are not automatically the obesity dose or brand.

    FDA-approved products have been reviewed for safety, effectiveness, and quality. Compounded copies have not. FDA consumer pages warn that unapproved GLP-1 drugs—including some compounded semaglutide and tirzepatide—are not the same as Wegovy, Ozempic, Mounjaro, or Zepbound. The agency has reported dosing errors that required hospitalization, concentrations that confuse milligrams with milliliters, salt forms that are not the approved active ingredient, and fraudulent labels. Compounding may be considered only when an available approved drug cannot meet a specific medical need. “Cheaper” and “same peptide” are not that need. After shortage resolutions, mass-market compounded look-alikes have faced increasing FDA enforcement.

    Monitoring is part of the medicine. Doses escalate slowly. Follow-up should track nausea, vomiting, constipation, hydration, gallbladder or pancreatitis symptoms, mood when relevant, and other glucose-lowering drugs that may need reduction. Because appetite and intake fall, the visit should also set protein targets and resistance training so a larger share of loss is fat rather than muscle. ACSM adult guidelines still include muscle-strengthening on two or more days weekly when safe. Stopping often leads to regain; discuss duration and a taper or maintenance plan before the first injection.

    This service does not replace nutrition care, sleep-apnea treatment, or indicated surgery. A telehealth mill that ships an unlabeled syringe without a contraindication review is not medication management. Ask for the exact FDA-approved name, the indication on the label, and who you call after hours for severe abdominal pain or repeated vomiting.

    • Prefer the FDA-approved product that matches your indication.
    • Pair every dose increase with protein, fluid, and strength check-ins.

    Benefits

    Can produce clinically meaningful weight loss and risk-factor change when the labeled product fits
    Compares incretin and non-incretin options by contraindication and comorbidity
    Distinguishes FDA-approved drugs from compounded or unapproved look-alikes
    Monitors gastrointestinal, gallbladder, mood, and hypoglycemia risks during titration
    Protects muscle with protein intake and resistance-training plans
    Sets a maintenance or discontinuation plan before the first dose

    The Procedure

    1

    Confirm indication and contraindications

    2

    Choose the exact FDA-approved product

    3

    Titrate and teach use

    4

    Monitor nutrition and muscle

    5

    Reassess benefit, access, and duration

    Preparation

    Bring every medicine and supplement, insurance formulary or prior-authorization papers, history of pancreatitis, gallbladder disease, or severe reflux, mood or eating-disorder history, and pregnancy plans. Write whether you were offered a compounded vial and the product name on any current pen. Note baseline strength or activity so muscle loss can be watched.

    Recovery & Aftercare

    There is no procedure downtime. Nausea, constipation, diarrhea, or low intake are common during titration and often ease if the dose is held or slowed. Keep fluids and protein up. Resume usual activity unless dizziness or dehydration appears. Call promptly for severe persistent abdominal pain, repeated vomiting, signs of dehydration, allergic reaction, pregnancy, or a sharp mood change.

    Risks & Considerations

    Risks vary by drug and include gastrointestinal symptoms, gallbladder disease, pancreatitis, dehydration, hypoglycemia when insulin or sulfonylureas are not adjusted, and rare but serious mood changes. GLP-1 labels carry warnings about medullary thyroid cancer history and MEN2. Compounded products add dosing-error, contamination, and unknown-potency risk. Fetal exposure should be avoided; use contraception as labeled. Do not combine unapproved peptides with a prescription incretin.

    Frequently Asked Questions

    References

    [1]

    NIDDK: Prescription Medications to Treat Overweight and Obesity

    https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
    [2]

    FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

    https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
    [3]

    FDA: Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss

    https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
    [4]

    FDA: Approval of Medication for Chronic Weight Management

    https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
    [5]

    Also Known As

    GLP-1 weight managementsemaglutide obesity medicationtirzepatide weight loss medicineanti-obesity medication managementcompounded vs FDA-approved GLP-1

    Quick Facts

    Duration

    Initial prescribing visits often 30–60 minutes; injection teaching may add time; follow-up 15–30 minutes.

    Cost Range

    Visit fees often $100–$300; FDA-approved incretins commonly hundreds to over $1,000/month without coverage, while older generics cost less and compounded look-alikes are a quality risk, not a true generic.

    Explore Clinics

    Find ClinicsBrowse ServicesBrowse by StateBrowse Locations

    Guides

    GuidesEvents

    For Providers

    Claim Your ClinicProvider Sign-inAdvertisePremium Listing & Pricing

    Company

    AboutLCF ScoreContact

    Legal

    AccessibilityPrivacyTerms of ServiceCookie PolicyMedical DisclaimerAll Legal Policies

    © 2026 Longevity Clinic Finder. All rights reserved.

    Designed by SMBPulse

    Your Privacy Choices
    Longevity Clinic Finder logo

    A global directory connecting individuals with longevity, wellness, and preventive health clinics. Discover treatments, explore providers, and find clinics near you or around the world.

    ACSM: Physical Activity Guidelines

    https://acsm.org/education-resources/trending-topics-resources/physical-activity-guidelines/

    Frequency

    Every 4–8 weeks during titration, then every 1–3 months once the dose and side-effect pattern are stable.

    Ideal Candidates

    Adults who meet the exact product indication after a contraindication and preference review, and who will use an FDA-approved medicine with scheduled follow-up. It is not for pregnancy, appearance-only requests, or people seeking an unmonitored compounded shortcut instead of labeled care.

    Looking for Weight Management?

    Explore nearby clinics, compare profiles, and find providers offering this treatment.

    Find Clinics Near You

    Related Treatment Guides

    • What Is Evidence-Based Weight Management?

      Weight Management

    • Bariatric Surgery Referral and Coordination

      Weight Management

    • Body Composition and Metabolic Assessment

      Weight Management

    Top Cities

    Explore a City
    • Atlanta, GA
    • Austin, TX
    • Boca Raton, FL
    • Charlotte, NC
    • Chicago, IL
    • Colorado Springs, CO
    • Dallas, TX
    • Denver, CO
    • Fort Lauderdale, FL
    • Houston, TX
    • Las Vegas, NV
    • Los Angeles, CA
    • Miami, FL
    • Naples, FL
    • Nashville, TN
    • New York, NY
    • Orlando, FL
    • Portland, OR
    • San Antonio, TX
    • San Diego, CA
    • San Francisco, CA
    • Sarasota, FL
    • Scottsdale, AZ
    • Tampa, FL
    • Tucson, AZ

    Explore Clinics

    Find ClinicsBrowse ServicesBrowse by StateBrowse Locations

    Guides

    GuidesEvents

    For Providers

    Claim Your ClinicProvider Sign-inAdvertisePremium Listing & Pricing

    Company

    AboutLCF ScoreContact

    Legal

    AccessibilityPrivacyTerms of ServiceCookie PolicyMedical DisclaimerAll Legal Policies

    © 2026 Longevity Clinic Finder. All rights reserved.

    Designed by SMBPulse

    Your Privacy Choices